The capital raise strengthens the company's balance sheet and ensures continued Nasdaq listing. However, investors should monitor the dilutive impact of the convertible preferred stock and placement agent fees. The company's ability to utilize these funds effectively will be key to future performance.
Price Chart
Executive Summary
Aspire Biopharma Holdings, Inc. completed a second closing of its private placement, issuing an additional 12,500 shares of Series A Convertible Preferred Stock for $10 million in gross proceeds. This brings the total offering to $21 million, including debt conversion. The company also amended its Certificate of Designation to designate 30,000 shares of Series A Convertible Preferred Stock. This capital raise helps the company meet Nasdaq's minimum equity requirement for continued listing.
Key Financial Metrics
Key Facts
- Completed second closing of private placement, raising $10 million in gross proceeds
- Total offering now $21 million, including $943,801 in debt conversion
- Amended Certificate of Designation to designate 30,000 shares of Series A Convertible Preferred Stock
- Company believes it now has stockholders equity in excess of $2.5 million, meeting Nasdaq's minimum requirement
- Placement agent fee paid was $900,000
Financial Impact
$10 million in gross proceeds from the second closing, $21 million total offering
Risk Factors
- Dilution from convertible preferred stock
- Placement agent fees reduce net proceeds
- Execution risk in utilizing the capital effectively
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-017115 |
| Document: 0001493152-26-017115-index-headers.html | 0001493152-26-017115 |
| Document: 0001493152-26-017115-index.html | 0001493152-26-017115 |
| Document: 0001493152-26-017115.txt | 0001493152-26-017115 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 20, 2026 27w ago | 8-K | $0.0200 $0.0243 | ▲ +21.50% | ▲ +14.72% | — |
Apr 16, 2026 27w ago | 8-K | $0.0200 $0.0200 | · 0.00% | ▼ −6.14% | — |
Apr 16, 2026 27w ago | 8-K | $0.0200 $0.0239 | ▲ +19.50% | ▲ +12.45% | — |
Apr 15, 2026 27w ago | EFFECT | $0.0200 $0.0200 | · 0.00% | ▼ −8.14% | — |
Apr 10, 2026 28w ago | S-1/A | $0.0200 $0.0200 | · 0.00% | ▲ +10.33% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers